Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.
You may also be interested in...
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
Merck enjoyed a good second quarter, beating sales expectations for Keytruda and other drugs, which helped offset losses related to patent expirations.
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.